AstraZeneca, a global, innovation-driven biopharmaceutical business, to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden.
The new plant will be focused on filling and packaging of protein therapeutics. It is anticipated that the new facility will supply medicines for clinical trial programmes of AstraZeneca and MedImmune, the company’s global biologics research and development arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.
{iframe}http://www.pharmabiz.com/NewsDetails.aspx?aid=88307&sid=2{/iframe}